Top Page
Vitasora Health
(OTC:VHL)
Vitasora Health (VHL) vs. iShares MSCI Australia ETF (EWA)
Vitasora Health Business Overview & Revenue Model
Vitasora Health Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Vitasora Health Technical Analysis
Vitasora Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $35.52M | ― | -50.50% | ― | 39.08% | 53.31% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
48 Neutral | AU$49.98M | ― | -8.08% | ― | -5.62% | -225.71% | |
46 Neutral | $72.99M | ― | -51.08% | ― | 10.22% | -2.94% | |
46 Neutral | AU$149.65M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$30.02M | ― | -135.33% | ― | -27.58% | 33.69% | |
40 Underperform | AU$47.31M | ― | -185.67% | ― | 492.19% | 12.16% |
Vitasora Health Corporate Events
Vitasora Health Limited has released a capital raise presentation, emphasizing that the information provided is not comprehensive investment advice and should be considered with caution. The company highlights the inherent risks and uncertainties in developing technology and urges stakeholders not to rely heavily on forward-looking statements as they are subject to change and may not guarantee future performance.
Vitasora Health Limited has successfully raised $11 million through a placement supported by institutional and long-term shareholders, reflecting strong investor confidence in the company’s strategy and execution capabilities. The funds will support Vitasora’s operations until it reaches cash flow breakeven in the second half of fiscal year 2026, enabling the company to expand its clinical operations, enhance its technology platform, and strengthen client relationships. This capital raise positions Vitasora to scale efficiently and generate long-term shareholder value, with additional commercial opportunities anticipated in the near future.
Vitasora Health has expanded its partnership with The Physician Alliance Corporation (TPAC) from a pilot program in Arizona to a full-scale value-based care agreement covering up to 15,000 Medicare patients. This agreement is expected to generate significant new revenue streams for Vitasora through guaranteed care management fees, reimbursed remote patient monitoring services, and performance bonuses linked to quality savings. The partnership positions Vitasora as a leader in the U.S. value-based care market and supports TPAC’s rapid growth strategy, potentially increasing its Medicare patient panel to 100,000 lives within three years. This strategic move enhances Vitasora’s industry positioning and offers a competitive edge for TPAC in attracting new physician practices.
Vitasora Health Limited has announced the expiry of its listed options VHLO on 30 June 2025, with an exercise price of $0.065 per option. Option holders have the choice to exercise, sell, or let the options expire. The company emphasizes the need for holders to act before the official quotation ceases on 24 June 2025. This announcement is crucial for stakeholders as it impacts the potential conversion of 76,186,219 options into fully paid ordinary shares, affecting the company’s capital structure and market positioning.
Vitasora Health Limited has issued a prospectus for the offer of 1,000 shares at a price of $0.045 per share, with the offer closing on June 5, 2025. This prospectus aims to remove secondary trading restrictions on the shares issued under the placement, and the securities offered should be considered speculative.
Vitasora Health Limited announced the release of 35,555,555 fully paid ordinary shares from escrow on June 3, 2025, which were initially issued to institutional and sophisticated investors. This move is in line with the company’s strategic efforts to enhance its financial flexibility and could potentially impact its market positioning by increasing the liquidity of its shares.
Vitasora Health Limited has announced a virtual investor update to discuss significant developments in the United States, which are expected to impact the company’s growth trajectory. The briefing will cover recent progress with U.S. partners, expansion milestones, and upcoming opportunities, highlighting the company’s strategic positioning in the healthcare industry and its potential implications for stakeholders.
Vitasora Health Limited announced a change in the director’s interest, with Nicholas Smedley acquiring 875,000 ordinary shares through a share placement approved at the company’s Extraordinary General Meeting on April 16, 2025. This acquisition reflects a strategic move to strengthen the director’s stake in the company, potentially impacting the company’s governance and signaling confidence in its future prospects.
Vitasora Health Limited has issued 1,750,000 fully paid ordinary shares, as announced in their recent ASX release. This move is part of their ongoing efforts to comply with regulatory requirements and maintain transparency with investors. The issuance of shares without disclosure under certain provisions of the Corporations Act indicates a strategic approach to capital management, potentially impacting the company’s financial structure and market positioning.
Vitasora Health Limited has announced the issuance of 1,750,000 fully paid ordinary securities, which will be quoted on the ASX as of May 15, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for growth initiatives.